title: [Utility of 123-I ioflupane SPECT in the assessment of patients with Parkinsonian syndrome and cerebral vasculopathy].
abstract: OBJECTIVE
  To assess the utility of 123-I Ioflupane SPECT (IS) in the identification of the origin of Parkinsonism (vascular or idiopathic) in patients with cerebral vasculopathy (CV) demonstrated by morphological imaging techniques. Also, to assess the therapeutic impact.
  
  
  METHODS
  42 patients (16 males and 26 females) with a Parkinsonian syndrome were studied. Average age was 78.7 years (50-88). A dose of 185 MBq of 123 I-Ioflupane was injected in all subjects. SPECT imaging was obtained 5 hours later. All patients had a CT and/or MRI. The final diagnoses, after a minimal follow-up of 12 months, was established by a neurologist expert in movement disorders, based on clinical and imaging features and response to treatment.
  
  
  RESULTS
  14 patients were diagnosed of functional vascular Parkinsonism by alteration of association pathways, 3 of structural vascular Parkinsonism (SVP) with anatomical and functional vascular lesion in striatum, 14 of Parkinson's disease (PD) with CV, 2 of mixed Parkinsonism (PD + SVP) and 9 with others diagnoses different to the previous. The result of IS changed the treatment in 7/42 patients.
  
  
  CONCLUSIONS
  The IS can have a complementary role to clarify the etiology of Parkinsonism in patients with cerebral vasculopathy. Interpretation of functional and anatomical images within the clinical context of each patient is necessary.
authors.affiliation: Servicio de Medicina Nuclear, Complejo Hospitalario de Ciudad Real. amgarcia@sescam.jccm.es
authors.forename: A M
authors.initials: AM
authors.lastname: García Vicente
authors.forename: J
authors.initials: J
authors.lastname: Vaamonde Cano
authors.forename: A
authors.initials: A
authors.lastname: Soriano Castrejón
authors.forename: C
authors.initials: C
authors.lastname: Martínez Delgado
authors.forename: P
authors.initials: P
authors.lastname: Talavera Rubio
authors.forename: V M
authors.initials: VM
authors.lastname: Poblete García
authors.forename: S
authors.initials: S
authors.lastname: Ruiz Solís
authors.forename: S
authors.initials: S
authors.lastname: Rodado Marina
authors.forename: M
authors.initials: M
authors.lastname: Cortés Romera
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000978:Antiparkinson Agents / Q000627:therapeutic use; D019090:Case Management; D002561:Cerebrovascular Disorders / Q000150:complications / Q000000981:diagnostic imaging*; D003342:Corpus Striatum / Q000098:blood supply / Q000000981:diagnostic imaging; D015140:Dementia, Vascular / Q000000981:diagnostic imaging; D003937:Diagnosis, Differential; D050483:Dopamine Plasma Membrane Transport Proteins / Q000032:analysis; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D020734:Parkinsonian Disorders / Q000139:chemically induced / Q000000981:diagnostic imaging* / Q000188:drug therapy / Q000209:etiology; D017729:Presynaptic Terminals / Q000000981:diagnostic imaging; D019275:Radiopharmaceuticals; D015899:Tomography, Emission-Computed, Single-Photon; D014326:Tropanes
chemical_list: D000978:Antiparkinson Agents; D050483:Dopamine Plasma Membrane Transport Proteins; D019275:Radiopharmaceuticals; D014326:Tropanes; C087552:2-carbomethoxy-8-(3-fluoropropyl)-3-(4-iodophenyl)tropane; D007980:Levodopa